Last reviewed · How we verify

NCT04674332

Long Acting Insulin Versus Multiple Dose Regimen for Control of Gestational Diabetes Mellitus

Completed Phase 2, PHASE3 Last updated 8 September 2021
What this trial tests

Phase 2, PHASE3 trial testing Long acting insulin in Long Acting Insulin in Control of Gestational Diabetes Mellitus in 148 participants. Completed in 14 December 2020.

Timeline
1 September 2019
Primary endpoint
14 December 2020
14 December 2020

Quick facts

Lead sponsorAin Shams University
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment148
Start date1 September 2019
Primary completion14 December 2020
Estimated completion14 December 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 18 to 45, female only, with Long Acting Insulin in Control of Gestational Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

multiple dose regimen as a standard treatment for gestational diabetes will be compared to long acting insulin

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Long acting insulin

Trials testing the same drug.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04674332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing